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Abstract
Background: Breast cancer is the most common malignancy with the highest incidence rates among women
worldwide. Triple-negative breast cancer (TNBC) represents the major phenotype of basal-like molecular subtype of
breast cancer, characterized by higher incidence in young women and a very poor prognosis. MicroRNAs (miRNAs)
are small non-coding RNAs playing significant role in the pathogenesis of many cancers including breast cancer.
Therefore, miRNAs are also potential prognostic and/or predictive biomarkers in triple-negative breast cancer
patients.
Methods: Thirty-nine TNBC patients with available formalin-fixed paraffin-embedded (FFPE) tissues were enrolled in
the study. MiR-34a, miR-34b, and miR-34c were analyzed using qRT-PCR and correlated to clinico-pathological
features of TNBC patients.
Results: Expression levels of miR-34b significantly correlate with disease free survival (DFS) (p = 0.0020, log-rank
test) and overall survival (OS) (p = 0.0008, log-rank test) of TNBC patients. No other significant associations between
miR-34a, miR-34b, and miR-34c with available clinical pathological data were observed.
Conclusions: MiR-34b expression negatively correlates with disease free survival and overall survival in TNBC
patients. Thus, miR-34b may present a new promising prognostic biomarker in TNBC patients, but independent
validations are necessary.
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Background
Breast cancer is the most common malignancy with the
highest incidence rates among women worldwide. It is a
heterogeneous disease due to complicated etiology
involving both genetic and environmental factors. This
malignity comprises multiple entities associated with
distinctive histological and biological features, clinical
presentations and behaviours and responses to therapy.
From the molecular point of view, breast cancers can be
divided into six molecular subtypes [1,2]. Breast cancer
with triple-negative phenotype (TNBC) characterized by
the absence of the estrogen receptor alpha (ERa), the
progesterone receptor (PgR), and the human epidermal
growth factor receptor-2 (HER2) expression represents
the major phenotype associated with basal-like molecu-
lar subtype of breast cancer. Additional molecular
alterations connected with TNBC are the loss of func-
tion of BRCA1 gene (>11%), and a higher rate of p53
mutations (>82%). Both are significantly associated not
only with breast cancer risk but also have been shown
to negatively affect clinical outcome of breast cancer
patients [3-5]. TNBC accounts for about 11% - 20% of
all breast cancers. It is diagnosed more frequently in
younger and premenopausal women and patients with
TNBC who have significantly increased risk of relapse
and death [3,4,6,7]. Because of a poor survival of TNBC
patients, there is a clinical need to identify new prognos-
tic biomarkers that can be used to predict a therapeutic
response and clinical outcomes in TNBC patients to
rationalize treatment decisions.
MicroRNAs (miRNAs) are highly conserved, small,
non-coding RNAs, 18-25 nucleotides in length, that act
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silencing their mRNA targets. Recent studies showed
that miRNAs regulate a significant number of onco-
genes, tumor suppressor genes, and genes associated
with the invasion, dissemination, and chemoresistance
of tumors. Therefore, these molecules play significant
roles in the pathogenesis of many cancers, including the
breast cancer and its triple-negative subtype [8,9]. Many
recent works described that the gene product of p53
which shows a high rate of mutations in TNBC patients,
activates transcription of the set of miRNAs including
the miR-34 family. The miR-34 family regulates cell
cycle progression, cellular senescence and apoptosis and,
as a consequence, could affect biological features of
TNBC [10-12]. The aim of this study was to quantify
expression levels of miR-34a, miR-34b, and miR-34c in
the clinical samples of TNBC, and to evaluate their
association with clinical- pathological features to identify
new prognostic and/or predictive biomarkers for TNBC
patients.
Materials and methods
Patients and samples
The study included a group of 39 clinical-pathological
characterized patients with histologically confirmed tri-
ple-negative breast cancer (TNBC) (Table 1). All
patients were females diagnosed with an early breast
cancer and were treated according to the best clinical
practices and protocols valid at the time of diagnosis.
All patients complied with the designed treatment
(except 3 women who refused the adjuvant therapy). A
relapse of the disease was documented in 27 (69%)
patients. Median follow-up time was 34 months for all
and 124 months for living patients. In the whole group,
the median DFS was16 months (range from 3.5 to 187
months) and median OS was 41 months (range from 13
to187 months). Informed consent approved by the local
Ethical Commission was obtained from each patient
before the treatment.
All samples were tissues collected surgically under the
supervision of an experienced pathologist. Immunohisto-
chemistry (IHC) evaluation was performed on formalin-
fixed paraffin-embedded (FFPE) samples. HER2 negativ-
ity was defined as either the nonexpression of HER2
protein (IHC score 0/1+) or normal HER2 gene status.
The expression of HER2 protein was determined by
DAKO Herceptest (DAKO, Sweden) and scored on a
qualitative scale from 0 to 3+ according to DAKO man-
ual and American Society of Clinical Oncology/College
of American Pathologists guideline recommendations
for human epidermal growth factor receptor 2 testing in
breast cancer. HER2 gene status was evaluated by FISH
method using Abbott PathVysion HER2 kit (Abbott
Laboratories, USA). HER2 gene status was considered as
negative (FISH non-amplified) in case where a HER2
gene/centromer of chromosome 17 ratio was less than
1.8. All tumors were IHC 0 and/or FISH non-amplified.
The estrogen receptor alpha (ERa) and progesterone
receptor (PgR) status was examined by IHC using anti-
bodies provided by Lab Vision (SP1 resp. SP2 monoclo-
nal rabbit antibody, Lab Vision Thermo Fisher
Scientific, USA). ERa and PgR status was considered
positive if more than 10% of cells were stained in cell
nuclei. However, all carcinomas included in our study
did not have any expression of ERa and PgR (i.e. 0%).
Clinical data were reviewed retrospectively from medical
records. Response to therapy was evaluated by using
RECIST criteria version 1.1.
MiRNA extraction
Small RNA-enriched total RNA was isolated from FFPE
samples using mirVana miRNA Isolation Kit (Ambion,
Table 1 Characteristics of TNBC patients
Total (n = 39) %
Age (years)
Median (range) 44 (29 - 75)
Grade
I 00
II 71 8
III 32 82
Histology
Medullary 61 5
Invasive ductal 33 85
BRCA1 status
Wild-type 82 1
Mutated 13 33
NA 18 46
T
1 10 26
2 21 54
3 41 0
4 41 0
N
0 17 44
1 13 33
2 71 8
3 25
Clinical stage
I 71 8
II 21 54
III 11 28
IV 00
Annotation: NA - not available
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trolled by UV spectrophotometry (A260:A280 > 2.0;
A260:A230 > 1.8) using Nanodrop ND-1000 (Thermo
Scientific, USA).
Real-time quantification of miRNAs by stem-loop RT PCR
Complementary DNA (cDNA) was synthesized from 10 ng
small RNA-enriched total RNA using gene-specific primers
and Taq-Man MicroRNA Reverse Transcription kit
according to the Taq-Man MicroRNA Assay protocol
(Applied Biosystems, USA). Real-Time PCR was performed
using the Applied Biosystems 7500 Real-Time PCR System
in accordance with the TaqMan MicroRNA Assay proto-
col. Reverse transcription as well as Real-Time PCR detec-
tion were carried out using hsa-miR-34a, hsa-miR-34b, and
hsa-miR-34c (Assay no. 4427975; Applied Biosystems,
USA). RNU6B (Assay no. 4427975; Applied Biosystems,
USA) was used as a reference gene. The threshold cycle
data were determined using the default threshold settings.
Statistical analysis
Statistical analysis of differences of miRNA expression
levels in TNBC groups that were divided on the basis of
clinical-pathological features were evaluated using the
Kruskall-Wallis test. Survival analyses were performed
by Kaplan-Meier method and the differences between
the survival curves were evaluated by the log-rank test
to determine statistical significance levels. Variables sig-
nificantly associated with DFS in univariate analyses
were subjected to a stepwise backward multivariate ana-
lysis. P values <0.05 were considered significant. Multi-
variate analysis was performed according to the Cox’s
proportional hazards regression model. The MedCalc
Version 11.4.2.0 (MedCalc Software, Belgium) was used
for all calculations.
Results
Survival analysis performed on the cohort of 39 TNBC
patients showed that expression of miR-34b in tumors
significantly correlates with a disease free survival (DFS)
(P = 0.0020, log-rank test) (Figure 1a) and an overall
survival (OS) (P = 0.0008, log-rank test) (Figure 1b) of
TNBC patients. If relative expression levels of miR-34b
were higher than zero, the patients were considered to
be positive. Neither correlations with OS nor DFS were
observed in the cases of miR-34a and miR-34c. Kruskal-
Wallis analyses indicated no significant associations of
miR-34a, miR-34b, and miR-34c with histology, BRCA1
status, clinical stage, grade, and regional lymph node
metastases (Table 1).
Discussion
TNBC is the most frequent phenotype associated with
basal-like molecular subtype of breast cancer characterized
mainly by ERa, PgR, and HER2 absence. Further typical
molecular alterations of TNBC are the loss of function of
B R C A 1g e n ea n dp 5 3m u t a t i o n s ,b o t hc o n s i d e r e dt ob e
biomarkers of a breast cancer risk and a worse prognosis
for breast cancer patients [4,5]. In this study, we have
focused on the expression levels of miR-34 family whose
members are transcriptionally activated mainly by p53.
Majority of the previous studies described miR-34 family
members as tumor suppressive miRNAs involved in the
execution of p53-driven apoptotic pathways [10,12-15].
Our data show that miR-34b expression levels negatively
correlate with a disease free survival (DFS) and an overall
survival (OS) in TNBC patients, indicating rather onco-
g e n i cr o l ei nt u m o rc e l l .T h es i m i l a r l yo n c o g e n i cf e a t u r e
of this miRNA was formerly described also in renal cell
carcinomas and undifferentiated gastric cancers where
higher expression levels of miR-34b in tumor tissues com-
pared to non-tumor tissues were observed [16-18]. From
the histopathological point of view, it is one of the features
of TNBCs that is poorly differentiated and, thus, miR-34b
expression could also be a marker of differentiation of the
state of tumor cells [19]. This assumption is also sup-
ported by the fact that miR-34b is predicted (miRWalk
Database) as a direct regulator of Notch2 which plays an
Figure 1 Kaplan-Meier survival curves estimating disease free survival (A) and overall survival (B) of TNBC patients according to miR-
34b expression levels.
Svoboda et al. Diagnostic Pathology 2012, 7:31
http://www.diagnosticpathology.org/content/7/1/31
Page 3 of 5important role in cell differentiation and is decreased in
breast cancer tumors with poor differentiation (Grade 3)
and a worse prognosis [20]. In breast cancer, Notch2 path-
way is also a potent pro-apoptotic signaling with inhibitory
effect on tumor growth in xenograft model [21]. Research
group of Nevanlinna et al. (2011) revealed that overexpres-
sion of another member of miR-34 family, miR-34a, is a
marker of an aggressive breast tumor phenotype (positive
nodal status, ER-negativity, high proliferation rate, high
grade, p53-positivity) [22]. Moreover, Dutta et al. has
shown that knockdown of miR-34a significantly sup-
pressed proliferation of MCF7 breast cancer cells [23].
These results together indicate that activation of miR-34
family could support proliferation, differentiation and
aggressiveness of breast cancer cells. Statistical analyses
have not shown any further significant association of miR-
34a/b/c with the available clinical-pathological features.
There is some evidence, however, that individual members
of miR-34 family do not have to be expressed in the same
rate; for example, in retinoblastoma cells or ovarian cancer
tissues. These findings could be caused by p53-indepen-
dent regulation of miR-34 family transcription that has
been described in the case of miR-34a [24].
We have evaluated expression levels of miR-34 family
in TNBC and came up with the following conclusion.
The survival analyses have shown that the expression of
miR-34b does negatively correlate with a disease free
survival and an overall survival of TNBC patients.
Therefore, we suggest that miR-34b could be a promis-
ing prognostic biomarker in TNBC patients. Our data
are, however, preliminary and require other validations
on a larger and independent group of TNBC patients.
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